Login to Your Account

NewCo News

Topical HDAC Inhibitor Could 'Shape' CTCL Care

By Marie Powers
Staff Writer

Friday, April 5, 2013
Shape Pharmaceuticals Inc. is not aiming to reshape the industry. The Cambridge, Mass.-based biotech has the more modest goal of advancing its single asset, topical histone deacetylase (HDAC) inhibitor SHP-141, in cutaneous T-cell lymphoma (CTCL) and, potentially, other inflammatory skin conditions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription